{"name":"RayzeBio, Inc.","slug":"rayzebio-inc","ticker":"","exchange":"","domain":"rayzebio.com","description":"RayzeBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision radiotherapeutics for cancer. The company's pipeline includes several compounds in various stages of clinical development, targeting specific tumor types with the aim of improving patient outcomes.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"RYZ101 Dose Level 3","genericName":"RYZ101 Dose Level 3","slug":"ryz101-dose-level-3","indication":"Other","status":"phase_1"},{"name":"RYZ801","genericName":"RYZ801","slug":"ryz801","indication":"Other","status":"phase_1"},{"name":"RYZ101 Dose Level -1","genericName":"RYZ101 Dose Level -1","slug":"ryz101-dose-level-1","indication":"Other","status":"phase_1"},{"name":"RYZ101 Dose Level 2","genericName":"RYZ101 Dose Level 2","slug":"ryz101-dose-level-2","indication":"Other","status":"phase_1"},{"name":"RYZ401","genericName":"RYZ401","slug":"ryz401","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RYZ101","genericName":"RYZ101","slug":"ryz101","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"RYZ101","genericName":"RYZ101","slug":"ryz101","phase":"phase_3","mechanism":"RYZ101 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"RYZ101 Dose Level 3","genericName":"RYZ101 Dose Level 3","slug":"ryz101-dose-level-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RYZ801","genericName":"RYZ801","slug":"ryz801","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RYZ101 Dose Level -1","genericName":"RYZ101 Dose Level -1","slug":"ryz101-dose-level-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RYZ101 Dose Level 2","genericName":"RYZ101 Dose Level 2","slug":"ryz101-dose-level-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RYZ401","genericName":"RYZ401","slug":"ryz401","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTWpmR2w2d3B1UVBYTG9kaW94dE5EY0E4MjBBTEJTWm45eFNwSXFMZHdnWWRkeHpVR0lUSThiYnMzbnlCLTRNdG1zRkEta3VRa0Z1WmpMQl9oS0xkY0dKSWVUZmpMZWNJc3M4bHVrc2RjQjI0SWpRbnI2bzgwWl80eXRFaENka2JmdGVHN0xkaXRMa3hTcWltbmpvRTFjd2JRS0t1OVNucjg1dktRVDVaUERTQkVKakxjNlh0QTlR?oc=5","date":"2025-07-14","type":"pipeline","source":"Fierce Pharma","summary":"BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis - Fierce Pharma","headline":"BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RLWQyNzNOaEM1RFhrdkxaNEdnMUxBei1yZ2FaNk5WRm10RHRVS3VlY09kRWRVc0VYcWJHX21ObVJhSkRSaFhZYU5nMm1HLWRfNEFN?oc=5","date":"2025-07-14","type":"pipeline","source":"FirstWord Pharma","summary":"BMS's RayzeBio unit opens $160M radiopharma plant in Indianapolis - FirstWord Pharma","headline":"BMS's RayzeBio unit opens $160M radiopharma plant in Indianapolis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQeXEydDYyVmFrWWk1STIwcGpLQWphTzVqNGx3ZVEwRjRnV2NOcFNsTEtYMlI5eUI0blFBc2ZiV2MzSG1tWHl4c2ZvRFZmX0Z5OWh5ekpvRDhKQzJmbDRPbUhwQkRJLVIyelZiZHRhMG5aQVc0cG5xcENaWVdMTkNxekJTUlc3NGJJMVhhbjhQNFhPbmpZV19jbmZFbWdnNkhtUC15Rw?oc=5","date":"2025-06-11","type":"deal","source":"Contract Pharma","summary":"Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio - Contract Pharma","headline":"Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNenBULVdHT2EwU0lOUmpORmJpN0NrT0ZwOHVkOXdMT2t3QlN6UkZJVmpwZ1RQLU5BSXpxVElRd3FLUGNpOXRzOUhQRWxzNjF6SzJJeGVjVXRidlJnV2t2R3pFRk5wRlBlVm9FRlo2WEFyYkU1NTAzT1lTZkNERklIbm1oZU82Y2ZUblg2NlN2ZzNjQjdVM2xPdGJ0LWNiQW1NdjZwY2g3UVRiZE45TDIw?oc=5","date":"2025-06-11","type":"deal","source":"Fierce Biotech","summary":"BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal - Fierce Biotech","headline":"BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdmZ6QUl6X2R0TUZTWjdfVU8tWW8wSUJsZFFrQjB3cEoxWTVjYUxwRzRYNWNKY1Z0Z2dMQ0swTmx2ai1QQlN4eDJqNF9zLTZXalgyaEFOTWFTeV9EbHJBcFhPQjZoVnNENHpYcno2c2tkUy1yaVNLeXIxbk96cGM2a1lNOUstam1BZVZKbkl1V2NvWHhLUF93LTRYNFU5V1BkUWpFSXN2N0c?oc=5","date":"2025-06-11","type":"deal","source":"BioSpace","summary":"BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem - BioSpace","headline":"BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-10","type":"pipeline","source":"GlobeNewswire","summary":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Compan","headline":"Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagno","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPY0N6a1haVkVOUjBkSGFyd202NWluT0hWMnFjOG1iTmVTSS1uVFpLaG1XLW9GZWUtMDhUSEpSV0tUeC1tcFctUW9TNjQ3Q2lZQTdROFZ1QnZXSEpyVHMwVFkwMmtYQzRsV2MyWVdzZDhCemQwa3l3OXAzOW4wVE43WjhLRk10UQ?oc=5","date":"2024-06-06","type":"trial","source":"Oncology Pipeline","summary":"Telix heads to the US, as RayzeBio runs into problems | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Telix heads to the US, as RayzeBio runs into problems | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPUG9WODU0cm5OWjR6ZnphcU5RX1FFSWkxY2VnODZKVENhRWsxN1NJemF2SGp6bU5vYVhqR2xDS0hFamE0ZllBQ3RhWmx6eC1IYnpCcWpBV05haFA0STBsWVBBbUsyZjE1LW9hcmtLWlBLQ0w1UmFPNWJMVFFsUl9mN2RZOA?oc=5","date":"2024-02-27","type":"deal","source":"Pharmaceutical Technology","summary":"Bristol Myers Squibb acquires RayzeBio for $4.1bn - Pharmaceutical Technology","headline":"Bristol Myers Squibb acquires RayzeBio for $4.1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNZ05iRTJXUXFONk9iSlFVSlBtdHM3eUl6UUdCLUlPOXBKV3dPREtKTUVxQ0xVSVlnRlpSWmREYmYzTXlQUFYyTHFDVWU2LV95NURQM3RHWDF1WkdlcnM3QzFVelh5M20xcFhyMXR0cnZqTW5fRzdjYmJPV2x3cnFFSHhucjdCVE9UWExaazlHZ0FRVkdMMjN6RFhBR0pDRTdx?oc=5","date":"2024-01-25","type":"deal","source":"BioPharma Dive","summary":"RayzeBio drew other pharma interest before Bristol Myers deal - BioPharma Dive","headline":"RayzeBio drew other pharma interest before Bristol Myers deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOTzhkSUJEeUU4aGNaSWNVckN5VW1ta3BldWtHX2QzT2FDSTRfdExtdlRpaVotQUJXVlNaYU13Qldxak9LdzFVWkF1OU94b2RJN2IyOERKeU9ycUtSaE12QWpPMHc4UTdHSUs4dER6eGd2aHE1Tk5KbHowczh2NS1QM3c4M28tR0pXdGJPX0hUaGpjSWd0Mk1YdVZiZw?oc=5","date":"2023-12-26","type":"deal","source":"WSJ","summary":"Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion - WSJ","headline":"Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPemhmSTBMSHlDdDlyRkhnMjEyUFkyclZ3NTVSS2E1VzkzbHNTc2RzVndheG1xTk9vR1Y5ZmFleE1OcEFXWGplc0xkamQwaW90ME5JUVB5ejRkVkUxRGdIZlczMW9DQm0wRmx1VHlLSDVhaC11bndOSkpJOFdGZTFwNW9IZnUxalJra291THVkSzhDbV9qaWdUSQ?oc=5","date":"2023-12-26","type":"deal","source":"Reuters","summary":"Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push - Reuters","headline":"Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOc1F1N2JUbXhlRlYySU12UGtHQzB3cVFVQzZjWm5ibTF2cUtaS2lmeEFWN2xOWmdCTlJCcGJJSXpQeXZxNE5vcUdzeWpPQkRZOUhwWG9PYTNzZkFMVGlzN3Z3eno3QzB6bGtISkdlT21FZkZXWmdMVWhsTW5rUUN3clN3bUZiWGd2OXFlZlB6V1R1MklVZ2xoYU9YR0ZfRFJPbXNZZFpnblllNHpYeUszVkhZWEgzVC1pLURablRROVhSMjNwM1o2eV9Ld21zQWp0YlFIUDVSM29YSFFWZFNpWXA4RDBWb0tmRGhSUDNDNnFoc3NDNW1QdzlaSmZSc0VJYzU4UE5yS3BpQjA4?oc=5","date":"2020-10-14","type":"pipeline","source":"Business Wire","summary":"RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics - Business Wire","headline":"RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutic","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":1,"phase_1":5},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}